Prolevi Bio develops a delayed release thyroid hormone formulation mimicking the circadian rhythm improving long-term side effects.
Prolevi Bio has raised $281K in total funding. The most recent round was Seed. The last funding was announced in September 2022.
Prolevi Bio's investors include Almi Invest.
Prolevi Bio is headquartered in Limhamn, Sweden.
Prolevi Bio develops a delayed release thyroid hormone formulation mimicking the circadian rhythm improving long-term side effects.
Prolevi Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prolevi Bio — Funding & Investors." VCBacked, September 14, 2022, https://www.vcbacked.co/company/prolevi-bio. Accessed September 30, 2026.
VCBacked. (2022). Prolevi Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/prolevi-bio
{{cite web |title=Prolevi Bio — Funding & Investors |url=https://www.vcbacked.co/company/prolevi-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated